TWD 70.8
(0.28%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -96.28 Million TWD | 8.06% |
2022 | -89.89 Million TWD | -4.88% |
2021 | -85.71 Million TWD | 20.83% |
2020 | -108.26 Million TWD | -7.15% |
2019 | -101.04 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -25.58 Million TWD | -0.1% |
2024 Q1 | -31.13 Million TWD | -12.75% |
2023 Q3 | -27.61 Million TWD | -81.45% |
2023 FY | -82.65 Million TWD | 8.06% |
2023 Q2 | -15.21 Million TWD | 11.19% |
2023 Q1 | -17.13 Million TWD | 34.33% |
2023 Q4 | -27.61 Million TWD | 0.0% |
2022 FY | -89.89 Million TWD | -4.88% |
2022 Q4 | -26.09 Million TWD | 0.0% |
2021 FY | -85.71 Million TWD | 20.83% |
2020 FY | -108.26 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Apex Biotechnology Corp. | 141.71 Million TWD | 167.939% |
Sinphar Pharmaceutical Co.,Ltd. | 286.05 Million TWD | 133.658% |
Panion & Bf Biotech Inc. | 156.82 Million TWD | 161.392% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 280.8 Million TWD | 134.287% |
GenMont Biotech Incorporation | 6.98 Million TWD | 1477.79% |
Abnova (Taiwan) Corporation | 47.19 Million TWD | 304.009% |
Adimmune Corporation | -722.74 Million TWD | 86.679% |
Tanvex BioPharma, Inc. | -2.1 Billion TWD | 95.417% |
Polaris Group | -1.84 Billion TWD | 94.787% |
Energenesis Biomedical CO.,LTD. | -261.83 Million TWD | 63.229% |
PELL Bio-Med Technology Co. Ltd. | -411.24 Million TWD | 76.588% |